Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1Phase 1 1

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 11NIH 8INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 2Tumor-Agnostic 1Thoracic 1Lymphoid 1

Conditions

Multiple Myeloma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

pembrolizumab 610Carboplatin 375Paclitaxel 283Cisplatin 268Gemcitabine 256Pemetrexed 194Bevacizumab 191Nivolumab 190Docetaxel 190Injections 169Cyclophosphamide 148atezolizumab 138Capecitabine 134Fluorouracil 133Oxaliplatin 132Dexamethasone 129Fulvestrant 115durvalumab 114130-nm albumin-bound paclitaxel 111fludarabine 102Cetuximab 101Leucovorin 97Rituximab 96venetoclax 90Lenalidomide 84Prednisone 79enzalutamide 78Azacitidine 76Irinotecan 74Ipilimumab 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Diphenhydramine × 1 year × Clear all
NCT07570173 2026-05-26

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting
340 enrolled
Lymphoid

Burkitt Lymphoma

NCT04165096 2026-05-13

MK-3475-01C

Merck Sharp & Dohme LLC

Phase 2 Completed
128 enrolled 14 charts
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05704049 2025-12-29

IZALCO

Sanofi

Phase 2 Active not recruiting
118 enrolled
Plasma cell

Multiple Myeloma

NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Sanofi

Phase 3 Active not recruiting
337 enrolled
Plasma cell

Multiple Myeloma

NCT03324113 2025-08-05

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

Sanofi

Phase 1 Completed
34 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡